Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Gianfranco Calogiuri*, Knut Brockow, Eustachio Nettis, Luigi Macchia, Caterina Foti and Angelo Vacca

DOI: 10.2174/1871530320666200515113736

DownloadDownload PDF Flyer Cite As
Promising Use of the New Biologics in the Management of Drug-Induced Hypersensitivity Reactions: Preliminary Approaches

Page: [1456 - 1469] Pages: 14

  • * (Excluding Mailing and Handling)

Abstract

Biologics are an innovative class of drugs that can selectively influence immunological responses at a cellular level. Although their use is usually restricted to some specific diseases, such as autoimmune pathologies and tumors, their “off-label” administration has increased widely in the last years. Drug treatment may induce hypersensitivity reactions which currently lack any gold standard therapy but maybe a future field of application for biologics. Agents like anti-IgE (Omalizumab) and Tumor Necrosis Factor-α inhibitors might be used in immediate-type and cell-mediated hypersensitivity caused by medications, respectively, and the first trials in that direction are being reported in the literature. In fact, the refined immunological mechanisms involved in the pathogenesis of drug hypersensitivity might respond successfully to this new class of drugs.

Keywords: Biologicals, drug hypersensitivity, omalizumab, infliximab, etanercept, mepolizumab anaphylaxis, drug-induced cutaneous adverse reactions.

Graphical Abstract

[1]
Pichler, W.J.; Hausmann, O. Classification of drug hypersensitivity into Allergic, p-i and pseudoallergic forms. Int. Arch. Allergy Immunol., 2016, 171(3-4), 166-179.
[http://dx.doi.org/10.1159/000453265 ] [PMID: 27960170]
[2]
Pourpak, Z.; Fazlollahi, M.R.; Fattahi, F. Understanding adverse drug reactions and drug allergies: principles, diagnosis and treatment aspects. Recent Pat. Inflamm. Allergy Drug Discov., 2008, 2(1), 24-46.
[http://dx.doi.org/10.2174/187221308783399289 ] [PMID: 19075990]
[3]
Pichler, W.J. Delayed drug hypersensitivity reactions. Ann. Intern. Med., 2003, 139(8), 683-693.
[http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00012 ] [PMID: 14568857]
[4]
Posadas, S.J.; Pichler, W.J. Delayed drug hypersensitivity reactions - new concepts. Clin. Exp. Allergy, 2007, 37(7), 989-999.
[http://dx.doi.org/10.1111/j.1365-2222.2007.02742.x ] [PMID: 17581192]
[5]
Pichler, W.J.; Adam, J.; Daubner, B.; Gentinetta, T.; Keller, M.; Yerly, D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med. Clin. North Am., 2010, 94(4), 645-664.xv..
[http://dx.doi.org/10.1016/j.mcna.2010.04.003] [PMID: 20609855]
[6]
Goh, T.K.; Pang, S.M.; Thirumoorthy, T.; Goh, S.G.N. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine. Singapore Med. J., 2008, 49(6), 507-510.
[PMID: 18581028]
[7]
Scheinfeld, N.; Wesson, K.; Perry, P.; Weinberg, J. Acute generalized exanthematous pustulosis resembling toxic epidermal necrolysis caused by famotidine. Acta Derm. Venereol., 2003, 83(1), 76-77.
[http://dx.doi.org/10.1080/00015550310002873 ] [PMID: 12636039]
[8]
Mizoguchi, S.; Setoyama, M.; Higashi, Y.; Hozumi, H.; Kanzaki, T. Eosinophilic pustular folliculitis induced by carbamazepine. J. Am. Acad. Dermatol., 1998, 38(4), 641-643.
[http://dx.doi.org/10.1016/S0190-9622(98)70137-9 ] [PMID: 9555813]
[9]
Matsuda, H.; Saito, K.; Takayanagi, Y.; Okazaki, T.; Kashima, K.; Ishikawa, K.; Kai, Y.; Takeo, N.; Hatano, Y.; Okamoto, O.; Fujiwara, S. Pustular-type drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to carbamazepine with systemic muscle involvement. J. Dermatol., 2013, 40(2), 118-122.
[http://dx.doi.org/10.1111/1346-8138.12028 ] [PMID: 23216243]
[10]
Caproni, M.; Torchia, D.; Schincaglia, E.; Volpi, W.; Frezzolini, A.; Schena, D.; Marzano, A.; Quaglino, P.; De Simone, C.; Parodi, A.; Barletta, E.; Fabbri, P. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br. J. Dermatol., 2006, 155(4), 722-728.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07398.x ] [PMID: 16965421]
[11]
Hirahara, K.; Kano, Y.; Mitsuyama, Y.; Takahashi, R.; Kimishima, M.; Shiohara, T. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. Clin. Exp. Dermatol., 2010, 35(8), 863-868.
[http://dx.doi.org/10.1111/j.1365-2230.2010.03820.x ] [PMID: 20456395]
[12]
Teraki, Y.; Kawabe, M.; Izaki, S. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol., 2013, 131(3), 907-909.
[http://dx.doi.org/10.1016/j.jaci.2012.08.042 ] [PMID: 23083672]
[13]
Ghislain, P.D.; Roujeau, J.C. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. Online J., 2002, 8(1), 5.
[PMID: 12165215]
[14]
Scherer, K.; Spoerl, D.; Bircher, A.J. Adverse drug reactions to biologics. J. Dtsch. Dermatol. Ges., 2010, 8(6), 411-426.
[PMID: 20136676]
[15]
Boyman, O.; Kaegi, C.; Akdis, M.; Bavbek, S.; Bossios, A.; Chatzipetrou, A.; Eiwegger, T.; Firinu, D.; Harr, T.; Knol, E.; Matucci, A.; Palomares, O.; Schmidt-Weber, C.; Simon, H.U.; Steiner, U.C.; Vultaggio, A.; Akdis, C.A.; Spertini, F. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy, 2015, 70(7), 727-754.
[http://dx.doi.org/10.1111/all.12616 ] [PMID: 25819018]
[16]
Babu, K.S.; Arshad, S.H.; Holgate, S.T. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin. Biol. Ther., 2001, 1(6), 1049-1058.
[http://dx.doi.org/10.1517/14712598.1.6.1049 ] [PMID: 11728235]
[17]
Di Domenico, M.; Bisogno, A.; Polverino, M.; De Rosa, C.; Ricci, V.; Capasso, A. Xolair in asthma therapy: an overview. Inflamm. Allergy Drug Targets, 2011, 10(1), 2-12.
[http://dx.doi.org/10.2174/187152811794352042 ] [PMID: 21184647]
[18]
Chang, T.W.; Shiung, Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J. Allergy Clin. Immunol., 2006, 117(6), 1203-1212.
[http://dx.doi.org/10.1016/j.jaci.2006.04.005 ] [PMID: 16750976]
[19]
Holgate, S.; Casale, T.; Wenzel, S.; Bousquet, J.; Deniz, Y.; Reisner, C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol., 2005, 115(3), 459-465.
[http://dx.doi.org/10.1016/j.jaci.2004.11.053 ] [PMID: 15753888]
[20]
Noga, O.; Hanf, G.; Brachmann, I.; Klucken, A.C.; Kleine-Tebbe, J.; Rosseau, S.; Kunkel, G.; Suttorp, N.; Seybold, J. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J. Allergy Clin. Immunol., 2006, 117(6), 1493-1499.
[http://dx.doi.org/10.1016/j.jaci.2006.02.028 ] [PMID: 16751018]
[21]
Savage, J.H.; Courneya, J.P.; Sterba, P.M.; Macglashan, D.W.; Saini, S.S.; Wood, R.A. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J. Allergy Clin. Immunol., 2012, 130(5), 1123-1129.e2.
[http://dx.doi.org/10.1016/j.jaci.2012.05.039 ] [PMID: 22800401]
[22]
Wu, K.C.P.; Jabbar-Lopez, Z.K. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria. J. Invest. Dermatol., 2015, 135(1), 13-15.
[http://dx.doi.org/10.1038/jid.2014.362 ] [PMID: 25501377]
[23]
Baldo, B.A. IgE and drug allergy: antibody recognition of ‘small’ molecules of widely varying structures and activities. Antibodies (Basel), 2014, 3, 56-91.
[http://dx.doi.org/10.3390/antib3010056]
[24]
Ghazavi, M.K.; Johnston, G.A. Insulin allergy. Clin. Dermatol., 2011, 29(3), 300-305.
[http://dx.doi.org/10.1016/j.clindermatol.2010.11.009 ] [PMID: 21496738]
[25]
Rojas, J.; Villalobos, M.; Martínez, M.S.; Chávez-Castillo, M.; Torres, W.; Mejías, J.C.; Miquilena, E.; Bermúdez, V. Successful management of insulin allergy and autoimmune polyendocrine syndrome type 4 with desensitization therapy and glucocorticoid treatment: a case report and review of the literature. Case Reports Immunol., 2014, 2014 394754
[http://dx.doi.org/10.1155/2014/394754 ] [PMID: 25548690]
[26]
Matheu, V.; Franco, A.; Perez, E.; Hernández, M.; Barrios, Y. Omalizumab for drug allergy. J. Allergy Clin. Immunol., 2007, 120(6), 1471-1472.
[http://dx.doi.org/10.1016/j.jaci.2007.07.037 ] [PMID: 17854881]
[27]
Cavelti-Weder, C.; Muggli, B.; Keller, C.; Babians-Brunner, A.; Biason-Lauber, A.; Donath, M.Y.; Schmid-Grendelmeier, P. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care, 2012, 35(6), e41-e42.
[http://dx.doi.org/10.2337/dc12-0115 ] [PMID: 22619293]
[28]
Yong, P.F.; Malik, R.; Arif, S.; Peakman, M.; Amiel, S.; Ibrahim, M.A.; Gough, A. Rituximab and omalizumab in severe, refractory insulin allergy. N. Engl. J. Med., 2009, 360(10), 1045-1047.
[http://dx.doi.org/10.1056/NEJMc0808282 ] [PMID: 19264698]
[29]
Lee, S.; Ballow, M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J. Allergy Clin. Immunol., 2010, 125(4), 814-820.
[http://dx.doi.org/10.1016/j.jaci.2010.02.025 ] [PMID: 20371395]
[30]
Mishra, S.; Connors, L.; Tugwell, B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet. Med., 2018, 35(5), 663-666.
[http://dx.doi.org/10.1111/dme.13591 ] [PMID: 29381818]
[31]
Pilette, C.; Coppens, N.; Houssiau, F.A.; Rodenstein, D.O. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J. Allergy Clin. Immunol., 2007, 120(4), 972-973.
[http://dx.doi.org/10.1016/j.jaci.2007.06.038 ] [PMID: 17716723]
[32]
Yalcin, A.D.; Gorczynski, R.M.; Cilli, A.; Strauss, L. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up. Clin. Lab., 2014, 60(9), 1561-1564.
[http://dx.doi.org/10.7754/Clin.Lab.2013.130302 ] [PMID: 25291953]
[33]
Singh, S.; Prakash, Y.S.; Linneberg, A. Agrawal1 A. Insulin and the lung: connecting asthma and metabolic syndrome. J. Allergy (Cairo), 2013, 627384, 8.
[http://dx.doi.org/10.1155/2013/627384]]
[34]
Casale, T.B.; Busse, W.W.; Kline, J.N.; Ballas, Z.K.; Moss, M.H.; Townley, R.G.; Mokhtarani, M.; Seyfert-Margolis, V.; Asare, A.; Bateman, K.; Deniz, Y. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol., 2006, 117(1), 134-140.
[http://dx.doi.org/10.1016/j.jaci.2005.09.036 ] [PMID: 16387596]
[35]
Averbeck, M.; Gebhardt, C.; Renner, R.; Simon, J.; Treudler, R. Omalizumab helps to induce tolerability in a patient with wasp venom allergy and repeated adverse reactions during specific immunotherapy. Allergy, 2008, 1406.
[36]
Galera, C.; Soohun, N.; Zankar, N.; Caimmi, S.; Gallen, C.; Demoly, P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J. Investig. Allergol. Clin. Immunol., 2009, 19(3), 225-229.
[http://dx.doi.org/10.1155/2010/207084] [PMID: 19610266]
[37]
Makrilia, N.; Syrigou, E.; Kaklamanos, I.; Manolopoulos, L.; Saif, M.W. Hypersensitivity reactions associated with platinum antineoplatic agents: a systematic review. Meal-based Drugs, 2010, 2010(207084), 1-11.
[38]
Caiado, J.; Venemalm, L.; Pereira-Santos, M.C.; Costa, L.; Barbosa, M.P.; Castells, M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J. Allergy Clin. Immunol. Pract., 2013, 1(5), 494-500.
[http://dx.doi.org/10.1016/j.jaip.2013.06.002 ] [PMID: 24565621]
[39]
Iwamoto, T.; Hirai, H.; Yamaguchi, N.; Kobayashi, N.; Sugimoto, H.; Tabata, T.; Okuda, M. Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcεRI. Cancer Sci., 2014, 105(11), 1472-1479.
[http://dx.doi.org/10.1111/cas.12538 ] [PMID: 25230301]
[40]
Keat, K.; Harnett, P.; Fulcher, D.A. Carboplatin desensitization. Ann. Allergy Asthma Immunol., 2007, 99(5), 468-469.
[http://dx.doi.org/10.1016/S1081-1206(10)60575-3 ] [PMID: 18051220]
[41]
Ojaimi, S.; Harnett, P.R.; Fulcher, D.A. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J. Allergy Clin. Immunol. Pract., 2014, 2(1), 105-106.
[http://dx.doi.org/10.1016/j.jaip.2013.08.009 ] [PMID: 24565780]
[42]
Lukawska, JJ; Thursfield, D; Rotiroti, G; Dziadzio, M; Brown, M Adjuvant use of omalizumab in beta-lactam desensitization. J. Allergy Immunol., 2017.1, 003.
[43]
Lee, J. Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy. Asia Pac. Allergy, 2014, 4(2), 126-128.
[http://dx.doi.org/10.5415/apallergy.2014.4.2.126 ] [PMID: 24809019]
[44]
Arroabarren, E.; Aznal, E.; Anda, M.; Sanchez-Valverde, F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization. Pediatr. Allergy Immunol., 2019, 30(4), 491-494.
[http://dx.doi.org/10.1111/pai.13049 ] [PMID: 30817035]
[45]
Gevaert, P.; Calus, L.; Van Zele, T.; Blomme, K.; De Ruyck, N.; Bauters, W.; Hellings, P.; Brusselle, G.; De Bacquer, D.; van Cauwenberge, P.; Bachert, C. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol., 2013, 131(1), 110-6.e1.
[http://dx.doi.org/10.1016/j.jaci.2012.07.047 ] [PMID: 23021878]
[46]
Lommatzsch, M.; Korn, S.; Buhl, R.; Virchow, J.C. Against all odds: anti-IgE for intrinsic asthma? Thorax, 2014, 69(1), 94-96.
[http://dx.doi.org/10.1136/thoraxjnl-2013-203738 ] [PMID: 23709757]
[47]
Szczeklik, A.; Nizankowska, E. Clinical features and diagnosis of aspirin induced asthma. Thorax, 2000, 55(Suppl. 2), S42-S44.
[http://dx.doi.org/10.1136/thorax.55.suppl_2.S42 ] [PMID: 10992556]
[48]
Mastalerz, L.; Setkowicz, M.; Sanak, M.; Szczeklik, A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J. Allergy Clin. Immunol., 2004, 113(4), 771-775.
[http://dx.doi.org/10.1016/j.jaci.2003.12.323 ] [PMID: 15100686]
[49]
Cardet, J.C.; White, A.A.; Barrett, N.A.; Feldweg, A.M.; Wickner, P.G.; Savage, J.; Bhattacharyya, N.; Laidlaw, T.M. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract., 2014, 2(2), 208-213.
[http://dx.doi.org/10.1016/j.jaip.2013.12.003 ] [PMID: 24607050]
[50]
Garcia, G.; Magnan, A.; Chiron, R.; Contin-Bordes, C.; Berger, P.; Taillé, C.; Devouassoux, G.; de Blay, F.; Couderc, L.J.; Didier, A.; O’Callaghan, D.S.; Girodet, P.O.; Bourdeix, I.; Le Gros, V.; Humbert, M. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest, 2013, 144(2), 411-419.
[http://dx.doi.org/10.1378/chest.12-1961 ] [PMID: 23579324]
[51]
Phillips-Angles, E.; Barranco, P.; Lluch-Bernal, M.; Dominguez-Ortega, J.; López-Carrasco, V.; Quirce, S. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. J. Allergy Clin. Immunol. Pract., 2017, 5(3), 842-845.
[http://dx.doi.org/10.1016/j.jaip.2016.12.013 ] [PMID: 28117272]
[52]
Bobolea, I.; Barranco, P.; Fiandor, A.; Cabañas, R.; Quirce, S. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J. Investig. Allergol. Clin. Immunol., 2010, 20(5), 448-449.
[PMID: 20945617]
[53]
Aksu, K.; Kurt, E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol. Immunopathol. (Madr.), 2013, 41(3), 208-210.
[http://dx.doi.org/10.1016/j.aller.2012.02.005 ] [PMID: 22763305]
[54]
Bergmann, K.C.; Zuberbier, T.; Church, M.K. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract., 2015, 3(3), 459-460.
[http://dx.doi.org/10.1016/j.jaip.2015.01.012 ] [PMID: 25648572]
[55]
Guillén, D.; Bobolea, I.; Calderon, O.; Fiandor, A.; Cabañas, R.; Heredia, R.; Quirce, S. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease. J. Investig. Allergol. Clin. Immunol., 2015, 25(2), 133-135.
[PMID: 25997307]
[56]
Lang, D.M.; Aronica, M.A.; Maierson, E.S.; Wang, X.F.; Vasas, D.C.; Hazen, S.L. Omalizumab can inhibit respiratory reaction during aspirin desensitization. Ann. Allergy Asthma Immunol., 2018, 121(1), 98-104.
[http://dx.doi.org/10.1016/j.anai.2018.05.007 ] [PMID: 29777744]
[57]
Yalcin, A.D.; Bisgin, A.; Gorczynski, R.M. IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm., 2012, 2012 720976
[http://dx.doi.org/10.1155/2012/720976] [PMID: 23316107]
[58]
Hayashi, H.; Mitsui, C.; Nakatani, E.; Fukutomi, Y.; Kajiwara, K.; Watai, K.; Sekiya, K.; Tsuburai, T.; Akiyama, K.; Hasegawa, Y.; Taniguchi, M. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol., 2016, 137(5), 1585-1587.e4.
[http://dx.doi.org/10.1016/j.jaci.2015.09.034 ] [PMID: 26559322]
[59]
Asero, R. Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria. Eur. Ann. Allergy Clin. Immunol., 2018, 50(5), 226-228.
[http://dx.doi.org/10.23822/EurAnnACI.1764-1489.36 ] [PMID: 29384107]
[60]
Walters, K.M.; White, A.A. Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria. Ann. Allergy Asthma Immunol., 2016, 117(5), 559-561.
[http://dx.doi.org/10.1016/j.anai.2016.08.020 ] [PMID: 27788887]
[61]
Calogiuri, G.; Nettis, E.; Mandurino-Mirizzi, A.; Di Leo, E.; Macchia, L.; Foti, C.; Vacca, A.; Kounis, N.G. Omalizumab For The Treatment of Persistent Drug Induced Urticaria Elicited By Thienopyridines: A Case Report. Antiinflamm. Antiallergy Agents Med. Chem., 2019, 19, 1-5.
[PMID: 31113348]
[62]
Uzun, R.; Yalcin, A.D.; Celik, B.; Bulut, T.; Yalcin, A.N. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (Anti-IgE) and pulse prednisolone. Am. J. Case Rep., 2016, 17, 666-671.
[http://dx.doi.org/10.12659/AJCR.899823 ] [PMID: 27634312]
[63]
Sánchez-Machín, I.; Iglesias-Souto, J.; Franco, A.; Barrios, Y.; Gonzalez, R.; Matheu, V. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin. Mol. Allergy, 2011, 9, 11.
[http://dx.doi.org/10.1186/1476-7961-9-11 ] [PMID: 21791043]
[64]
Amat, F.; Tallon, P.; Foray, A.P.; Michaud, B.; Lambert, N.; Saint-Pierre, P.; Chatenoud, L.; Just, J. Control of asthma by omalizumab: the role of CD4+ Foxp3+ regulatory T cells. Clin. Exp. Allergy, 2016, 46(12), 1614-1616.
[http://dx.doi.org/10.1111/cea.12839 ] [PMID: 27770456]
[65]
Rodriguez, H.; Fahrenholz, J. Omalizumab treatment for prevention of anaphylaxis. Curr. Treat. Options Allergy, 2014, 1, 278-286.
[http://dx.doi.org/10.1007/s40521-014-0025-x]
[66]
Prieto-García, A.; Noguerado, B.; Rojas, P.; Torrado, I.; Rodríguez-Fernández, A.; Tornero, P. Unexpected anaphylaxis after completing a desensitization protocol to oxaliplatin: successful adjuvant use of omalizumab. J. Investig. Allergol. Clin. Immunol., 2019, 29(1), 53-55.
[http://dx.doi.org/10.18176/jiaci.0326 ] [PMID: 30785102]
[67]
Woolridge, K.F.; Boler, P.L.; Lee, B.D. Tumor necrosis factor α inhibitors in the treatment of toxic epidermal necrolysis. Cutis, 2018, 101(1), E15-E21.
[PMID: 29529123]
[68]
Klinkhoff, A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs, 2004, 64(12), 1267-1283.
[http://dx.doi.org/10.2165/00003495-200464120-00001 ] [PMID: 15200343]
[69]
Fischer, M.; Fiedler, E.; Marsch, W.C.; Wohlrab, J. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br. J. Dermatol., 2002, 146(4), 707-709.
[http://dx.doi.org/10.1046/j.1365-2133.2002.46833.x ] [PMID: 11966713]
[70]
Al-Shouli, S.; Abouchala, N.; Bogusz, M.J.; Al-Tufail, M.; Therstrup-Pedersen, K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm. Venereal,, 2005, 85(6), 534-535.
[http://dx.doi.org/10.1080/00015550510037062] [PMID: 16396808]
[71]
Hunger, R.E.; Hunziker, T.; Buettiker, U.; Braathen, L.R.; Yawalkar, N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment. J. Allergy Clin. Immunol., 2005, 116(4), 923-924.
[http://dx.doi.org/10.1016/j.jaci.2005.06.029 ] [PMID: 16210071]
[72]
Wojtkiewicz, A.; Wysocki, M.; Fortuna, J.; Chrupek, M.; Matczuk, M.; Koltan, A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm. Venereol., 2008, 88(4), 420-421.
[PMID: 18709327]
[73]
Kreft, B.; Wohlrab, J.; Bramsiepe, I.; Eismann, R.; Winkler, M.; Marsch, W.C. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab. J. Dermatol., 2010, 37(10), 904-906.
[http://dx.doi.org/10.1111/j.1346-8138.2010.00893.x ] [PMID: 20860742]
[74]
Zárate-Correa, L.C.; Carrillo-Gómez, D.C.; Ramírez-Escobar, A.F.; Serrano-Reyes, C. Toxic epidermal necrolysis successfully treated with infliximab. J. Investig. Allergol. Clin. Immunol., 2013, 23(1), 61-63.
[PMID: 23653980]
[75]
Scott-Lang, V.; Tidman, M.; McKay, D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr. Dermatol., 2014, 31(4), 532-534.
[http://dx.doi.org/10.1111/pde.12029 ] [PMID: 23072342]
[76]
White, J.C.; Appleman, S. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis. Pediatrics, 2014, 134(4), e1194-e1198.
[http://dx.doi.org/10.1542/peds.2013-2239 ] [PMID: 25246624]
[77]
Nassif, A.; Moslehi, H.; Le Gouvello, S.; Bagot, M.; Lyonnet, L.; Michel, L.; Boumsell, L.; Bensussan, A.; Roujeau, J.C. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol., 2004, 123(5), 850-855.
[http://dx.doi.org/10.1111/j.0022-202X.2004.23439.x ] [PMID: 15482470]
[78]
Gaitanis, G1.; Spyridonos, P; Patmanidis, K; Koulouras, V; Nakos, G; Tzaphlidou, M; Bassukas, I.D. Treatment oftoxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology, 2012, 224(2), 134-139.
[http://dx.doi.org/10.1159/000338202]
[79]
Patmanidis, K.; Sidiras, A.; Dolianitis, K.; Simelidis, D. Combination of Infliximab and high-doseintravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep. Dermatol. Med., 2012, 1-3 Article ID 915314
[http://dx.doi.org/10.1155/2012/915314] [PMID: 23259092]
[80]
Paquet, P.; Jennes, S.; Rousseau, A.F.; Libon, F.; Delvenne, P.; Piérard, G.E. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns, 2014, 40(8), 1707-1712.
[http://dx.doi.org/10.1016/j.burns.2014.01.027 ] [PMID: 24726294]
[81]
Viard, I1.; Wehrli, P.; Bullani, R.; Schneider, P.; Holler, N.; Salomon, D.; Hunziker, T. Saurat JH, Tschopp J, French LE. Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science, 1998, 282, 490-493.
[http://dx.doi.org/10.1126/science.282.5388.490]
[82]
Famularo, G.; Di Dona, B.; Canzona, F.; Girardelli, C.R.; Cruciani, G. Etanercept for toxic epidermal necrolysis. Ann. Pharmacother., 2007, 41(6), 1083-1084.
[http://dx.doi.org/10.1345/aph.1K001 ] [PMID: 17456541]
[83]
Gubinelli, E.; Canzona, F.; Tonanzi, T.; Raskovic, D.; Didona, B. Toxic epidermal necrolysis successfully treated with etanercept. J. Dermatol., 2009, 36(3), 150-153.
[http://dx.doi.org/10.1111/j.1346-8138.2009.00616.x ] [PMID: 19335689]
[84]
Paradisi, A.; Abeni, D.; Bergamo, F.; Ricci, F.; Didona, D.; Didona, B. Etanercept therapy for toxic epidermal necrolysis. J. Am. Acad. Dermatol., 2014, 71(2), 278-283.
[http://dx.doi.org/10.1016/j.jaad.2014.04.044 ] [PMID: 24928706]
[85]
Pham, C.H.; Gillenwater, T.J.; Nagengast, E.; McCullough, M.C.; Peng, D.H.; Garner, W.L. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Burns, 2019, 45(7), 1634-1638.
[http://dx.doi.org/10.1016/j.burns.2018.12.018 ] [PMID: 31466921]
[86]
Wang, C.W.; Yang, L.Y.; Chen, C.B.; Ho, H.C.; Hung, S.I.; Yang, C.H.; Chang, C.J.; Su, S.C.; Hui, R.C.; Chin, S.W.; Huang, L.F.; Lin, Y.Y.; Chang, W.Y.; Fan, W.L.; Yang, C.Y.; Ho, J.C.; Chang, Y.C.; Lu, C.W.; Chung, W.H. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J. Clin. Invest., 2018, 128(3), 985-996.
[http://dx.doi.org/10.1172/JCI93349 ] [PMID: 29400697]
[87]
Lee, Y.Y.; Ko, J.H.; Wei, C.H.; Chung, W.H. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Zhonghua Pifuke Yixue Zazhi, 2013, 31, 78-81.
[http://dx.doi.org/10.1016/j.dsi.2012.06.005]
[88]
Wang, R.; Zhong, S.; Tu, P.; Li, R.; Wang, M. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Dermatol. Ther. (Heidelb.), 2019, 32(4) e12832
[http://dx.doi.org/10.1111/dth.12832 ] [PMID: 30659711]
[89]
Chong, I.; Chao, A. Steven Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: a case report. Perm. J., 2017, 21, 16-060.
[http://dx.doi.org/10.7812/TPP/16-060 ] [PMID: 28488978]
[90]
Ling, X.; Shi, X.; Chen, L. Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-α antagonist: A case study. Exp. Ther. Med., 2017, 14(6), 5727-5732.
[http://dx.doi.org/10.3892/etm.2017.5336 ] [PMID: 29285114]
[91]
Trujillo-Trujillo, M.J.; González-Mancebo, E.; Gandolfo-Cano, M.; Mohedano-Vicente, E.; Martínez-Morán, C. Deflazacort-induced erythema multiforme exudativum successfully treated with a single dose of etanercept. J. Investig. Allergol. Clin. Immunol., 2018, 28(5), 338-339.
[http://dx.doi.org/10.18176/jiaci.0277 ] [PMID: 30350788]
[92]
Gavigan, G.M.; Kanigsberg, N.D.; Ramien, M.L. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. J. Cutan. Med. Surg., 2018, 22(5), 514-515.
[http://dx.doi.org/10.1177/1203475418758989 ] [PMID: 29421925]
[93]
Coulombe, J.; Belzile, E.; Duhamel, A.; Rault, P.; Buteau, C.; DeBruycker, J.J.; Bussières, J.F. Pediatric SJS/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept. J. Cutan. Med. Surg., 2019, 23(5), 547-550.
[http://dx.doi.org/10.1177/1203475419861078 ] [PMID: 31478770]
[94]
Didona, D.; Paolino, G.; Garcovich, S.; Caposiena Caro, R.D.; Didona, B. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J. Eur. Acad. Dermatol. Venereol., 2016, 30(10), e83-e84.
[http://dx.doi.org/10.1111/jdv.13330 ] [PMID: 26428058]
[95]
Schaerli, P.; Britschgi, M.; Keller, M.; Steiner, U.C.; Steinmann, L.S.; Moser, B.; Pichler, W.J. Characterization of human T cells that regulate neutrophilic skin inflammation. J. Immunol., 2004, 173(3), 2151-2158.
[http://dx.doi.org/10.4049/jimmunol.173.3.2151 ] [PMID: 15265952]
[96]
Gencoglan, G.; Tosun, M.; Aktepe, F. The molecular mechanism of etanercept, an anti-tumour necrosis factor-α receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis. J. Dermatolog. Treat., 2009, 20(4), 241-245.
[http://dx.doi.org/10.1080/09546630802683843 ] [PMID: 19657917]
[97]
Meiss, F.; Helmbold, P.; Meykadeh, N.; Gaber, G.; Marsch, W.Ch.; Fischer, M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J. Eur. Acad. Dermatol. Venereol., 2007, 21(5), 717-719.
[http://dx.doi.org/10.1111/j.1468-3083.2006.02026.x ] [PMID: 17448012]
[98]
Sadighha, A. Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research. Int. J. Dermatol., 2009, 48(8), 913-914.
[http://dx.doi.org/10.1111/j.1365-4632.2008.04020.x ] [PMID: 19659879]
[99]
Kavala, M.; Zindanci, I.; Türkoglu, Z.; Can, B.; Kocatürk, E.; Senol, S. Topaloglu1, F Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect. Case Reports Dermatol. Med., 2013, 1-3 . Article ID 601412
[100]
Vasconcelos, L.M.F.; Teixeira, F.M.; Francelino, E.V.; Almeida, T.L.; Bomfim, L. Acute generalized exanthematous pustulosis in a 51-year-old patient under etanercept treatment for psoriasis. J. Pharmacovigil., 2014, 2, 1-4.
[101]
Edwards, D.; Boritz, E.; Cowen, E.W.; Brown, R.S. Erythema multiforme major following treatment with infliximab. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2013, 115(2), e36-e40.
[http://dx.doi.org/10.1016/j.oooo.2012.08.001 ] [PMID: 23036796]
[102]
Worsnop, F.; Wee, J.; Natkunarajah, J.; Moosa, Y.; Marsden, R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin. Exp. Dermatol., 2012, 37(8), 879-881.
[http://dx.doi.org/10.1111/j.1365-2230.2012.04357.x ] [PMID: 22548502]
[103]
Favalli, E.G.; Desiati, F.; Atzeni, F.; Sarzi-Puttini, P.; Caporali, R.; Pallavicini, F.B.; Gorla, R.; Filippini, M.; Marchesoni, A. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun. Rev., 2009, 8(3), 266-273.
[http://dx.doi.org/10.1016/j.autrev.2008.11.002 ] [PMID: 19022409]
[104]
Rezakovic, S.; Pastar, Z.; Kostovic, K. Cutaneous adverse drug reactions caused by antituberculosis drugs. Inflamm. Allergy Drug Targets, 2014, 13(4), 241-248.
[http://dx.doi.org/10.2174/1871528113666140717113358 ] [PMID: 25039910]
[105]
Cantini, F.; Niccoli, L.; Goletti, D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J. Rheumatol. Suppl., 2014, 91, 47-55.
[http://dx.doi.org/10.3899/jrheum.140102 ] [PMID: 24789000]
[106]
Olson, D.; Watkins, L.K.; Demirjian, A.; Lin, X.; Robinson, C.C.; Pretty, K.; Benitez, A.J.; Winchell, J.M.; Diaz, M.H.; Miller, L.A.; Foo, T.A.; Mason, M.D.; Lauper, U.L.; Kupfer, O.; Kennedy, J.; Glodé, M.P.; Kutty, P.K.; Dominguez, S.R. Outbreak of mycoplasma pneumoniae-associated Stevens-Johnson syndrome. Pediatrics, 2015, 136(2), e386-e394.
[http://dx.doi.org/10.1542/peds.2015-0278 ] [PMID: 26216320]
[107]
Mpofu, S.; Fatima, F.; Moots, R.J. Anti-TNF-α therapies: they are all the same (aren’t they?). Rheumatology (Oxford), 2005, 44(3), 271-273.
[http://dx.doi.org/10.1093/rheumatology/keh483 ] [PMID: 15561736]
[108]
Vural, S.; Arakawa, A. Arakawa YPrinz JC. The teherapeutic potential of TNF-alpha antagonists in toxic epidermal necrolysis: insight from cases and adverse event report. J. Eur. Acad. Dermatol. Venereol., 2018, 32, e418-e419.
[http://dx.doi.org/10.1111/jdv.15006 ] [PMID: 29705991]
[109]
Menzies-Gow, A.; Flood-Page, P.; Sehmi, R.; Burman, J.; Hamid, Q.; Robinson, D.S.; Kay, A.B.; Denburg, J. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol., 2003, 111(4), 714-719.
[http://dx.doi.org/10.1067/mai.2003.1382 ] [PMID: 12704348]
[110]
Roufosse, F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front. Med. (Lausanne), 2018, 5, 49.
[http://dx.doi.org/10.3389/fmed.2018.00049 ] [PMID: 29682504]
[111]
Shiohara, T.; Kano, Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin. Drug Saf., 2017, 16(2), 139-147.
[PMID: 27936971]
[112]
Ange, N.; Alley, S.; Fernando, S.L.; Coyle, L.; Yun, J. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab. J. Allergy Clin. Immunol. Pract., 2018, 6(3), 1059-1060.
[http://dx.doi.org/10.1016/j.jaip.2017.10.020 ] [PMID: 29133221]
[113]
Thein, O.S.; Sutton, B.; Thickett, D.R.; Parekh, D. Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. BMJ Case Rep., 2019, 12(10) e231355
[http://dx.doi.org/10.1136/bcr-2019-231355 ] [PMID: 31604720]
[114]
Choquet-Kastylevsky, G.; Intrator, L.; Chenal, C.; Bocquet, H.; Revuz, J.; Roujeau, J.C. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br. J. Dermatol., 1998, 139(6), 1026-1032.
[http://dx.doi.org/10.1046/j.1365-2133.1998.02559.x ] [PMID: 9990366]
[115]
Hagin, D.; Shacham, Y.; Kivity, S.; Benor, S. Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm. J. Allergy Clin. Immunol. Pract., 2019, 7(3), 1076-1077.
[http://dx.doi.org/10.1016/j.jaip.2018.07.045 ] [PMID: 30172017]
[116]
Paul-Pletzer, K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc), 2006, 42(9), 559-576.
[http://dx.doi.org/10.1358/dot.2006.42.9.1025692 ] [PMID: 17028666]
[117]
Correia, O.; Delgado, L.; Barbosa, I.L.; Campilho, F.; Fleming-Torrinha, J. Increased interleukin 10, tumor necrosis factor α, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J. Am. Acad. Dermatol., 2002, 47(1), 58-62.
[http://dx.doi.org/10.1067/mjd.2002.120473 ] [PMID: 12077582]
[118]
Wang, F.; Gao, X.; Chen, X.; Tang, X.; Chen, H.; Han, J. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. J. Dermatol., 2019, 46(11), 1035-1038.
[http://dx.doi.org/10.1111/1346-8138.15058 ] [PMID: 31436331]
[119]
Morsy, H.; Taha, E.A.; Nigm, D.A.; Shahin, R.; Youssef, E.M.K. Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. Clin. Exp. Dermatol., 2017, 42(8), 868-873.
[http://dx.doi.org/10.1111/ced.13213 ] [PMID: 28940568]
[120]
Patel, D.D.; Lee, D.M.; Kolbinger, F.; Antoni, C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis., 2013, 72(Suppl. 2), ii116-ii123.
[http://dx.doi.org/10.1136/annrheumdis-2012-202371 ] [PMID: 23253932]
[121]
Khan, D.A. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann. Allergy Asthma Immunol., 2016, 117(2), 115-120.
[http://dx.doi.org/10.1016/j.anai.2016.05.013 ] [PMID: 27499538]